Transcript Highlights:

• I was formerly chief marketing officer for a global pharmaceutical company where I was beaten nearly
• I worked for the subsidiary Stratford Pharmaceuticals. I lost my livelihood.
• I was formerly chief marketing officer for a global pharmaceutical company where I was beat nearly to
• I worked for the subsidiary Stratford Pharmaceuticals. I lost my livelihood. I agree.
• I worked for the subsidiary Stratford Pharmaceuticals. I lost my livelihood.

Bills: S0212, S0656, S0682, S0810, S0812, S0890, S0892, S0900, S0928, S1084, S1284

Keywords: sexual offender, sexual predator, sex offender registry, child protection, residency restriction, loitering, proximity restriction, public swimming pool, school safety, child care facility, day care center, park, playground, conditional release, probation, community control, warrantless arrest, background check, registry screening, minor victims

Summary: The committee took up a series of criminal justice and public safety bills. SB 1084, which exempts certain identifying and location information for non-legal support staff in state attorneys’ offices from public records requests, was supported by prosecuting attorneys and reported favorably. SB 212, as amended, created new restrictions related to sexual offenders and predators, including a 200-foot restricted presence provision near certain locations and updated notification/supervision requirements; it drew strong opposition from researchers, advocates, and affected families who argued it lacked evidence and would increase homelessness, but it was reported favorably. SB 682, addressing domestic violence, coercive control, strangulation, animal abuse, injunctions, and related training and enforcement issues, received emotional survivor testimony and support from animal welfare and law enforcement groups and was reported favorably. SB 656, creating and renaming FDLE Internet Crimes Against Children funding and grant programs, was amended and reported favorably and unanimously. The committee also considered SB 810 on sealing criminal history records, which would expand eligibility for some non-conviction records and one low-level misdemeanor conviction after waiting periods and judicial review; supporters said Florida is unusually restrictive, while one senator raised concerns about the scope, and the bill was reported favorably. SB 890, creating a standalone battery by strangulation offense applicable outside domestic relationships, was reported favorably after the sponsor said it would close a gap in current law. SB 892, revising habitual offender and violent career criminal sentencing procedures and notice requirements, was reported favorably, with defense lawyers supporting the clearer pretrial notice. SB 928, “Missy’s Law,” requiring immediate remand to custody after conviction of certain dangerous crimes, was amended to include computer pornography/child exploitation offenses and reported favorably after a family member of the namesake victim testified in support. Later, SB 1284 modernized arrest and search warrant statutes, expanding judicial summons options for some misdemeanors and broadening warrant/arrest authority in certain DUI, injunction, domestic violence, and misdemeanor force cases; defense lawyers supported the judicial-discretion portions but raised concerns about DUI/BUI arrests, and the bill was reported favorably. Finally, SB 812, a technical companion to SB 810 updating public records treatment for sealed criminal history records, was amended to clarify prosecutorial access for later cases and reported favorably. Several bills were supported by law enforcement, prosecutors, and advocacy groups, while others drew opposition from civil liberties, treatment, homelessness, and criminal defense advocates. The meeting adjourned after members recorded additional votes on selected tabs.

Transcript Highlights:

• It's a huge benefit to the pharmaceutical industry.
• And those pharmaceutical companies can then scale It translates discoveries into products, and those
• Right now, the U.S. has the privilege of leading the world in scientific advancement for pharmaceutical
• I think that we should lean into it and figure out ways to support not just the pharmaceutical industry
• As you've probably read, there's a lot of pharmaceutical companies that have advertised that they're

Summary: The Assembly Select Committee on Biotechnology and Medical Technology met on August 19, 2025 to examine the effects of federal grant cuts, tariff uncertainty, and related policy changes on California’s biotech, medtech, and academic research ecosystem. The chair and panelists emphasized California’s outsized role in the industry, describing major clusters in the Bay Area, Los Angeles, and San Diego, and explaining how research, startup formation, manufacturing, and clinical trials are interconnected across the state. Speakers from Biocom California, California Life Sciences, Farma, UC, Stanford, CSU Biotech, and UCLA all argued that NIH and NSF funding are foundational to discovery, workforce training, and commercialization, and that disruptions are already chilling venture capital, startup formation, and hiring. Witnesses described several concrete impacts: suspended or terminated grants, reduced doctoral admissions, fewer training opportunities, canceled retreats and internships, and anxiety among graduate students and early-career researchers. UC reported hundreds of millions of dollars in suspended or terminated NIH and NSF funding, while Stanford said more than a thousand training and career-development grants nationwide have been frozen or ended, affecting multiple trainees per grant. CSU Biotech said 133 federal grants had been terminated, scaled back, or canceled, totaling about $140 million, including nearly $30 million from NIH and NSF. Industry representatives also warned that proposed antitrust limits on mergers and acquisitions could undermine the standard biotech exit path and further deter investment. Committee members asked about the duration of the disruption, the possibility of state action to offset federal losses, and whether California could better support workforce development, manufacturing, and R&D tax credits. Panelists urged the Legislature to preserve and expand state support for STEM education, internships, apprenticeship pathways, manufacturing incentives, and the R&D tax credit, and to consider infrastructure and housing as part of competitiveness. They also noted that tariffs are already raising costs for medtech components and building materials, and that China is increasingly competing for R&D, talent, and licensing deals. No formal votes or bill actions were taken at the hearing; the meeting was informational and focused on testimony and discussion.

Transcript Highlights:

• It will give you some sense of, you know, one of the biggest ones is the pharmaceuticals.
• It will give you some sense of, you know, one of the biggest ones is the pharmaceuticals.
• We know that the pharmaceutical spend is drastically increasing nationwide. Let's see.
• </c><02:02:07.119><c> cost</c> think about uh what pharmaceutical cost think about uh what pharmaceutical
• </c><02:05:48.280><c> Services</c> I mean pharmace pharmaceutical Services I mean pharmace pharmaceutical

Keywords: 928, house, all

Summary: The House Finance Division III held an informational hearing on Medicaid, Medicare, Choices for Independence, and related financing, while postponing nursing facility financing and the county cap discussion to a later date. DHHS officials Ann Landry, Jonathan Ballard, and Medicaid Director Henry Litman provided an overview of Medicaid’s role, noting it is a federal-state partnership with state-specific eligibility and benefits, and emphasizing that Medicaid is a major funding and programmatic support for other DHHS initiatives. They also distinguished Medicaid from Medicare and explained that Medicaid funding is not the same as grant funding, though some providers may also receive federal grants through other channels. The presentation focused on New Hampshire’s relatively small Medicaid program and why it differs from national averages. Officials said about 184,000 residents are covered, roughly one in seven Granite Staters compared with one in five nationally, and attributed the difference largely to the state’s higher per-capita income and older population. They highlighted that about 65% of Medicaid-enrolled adults in New Hampshire are working, that only 22% of births are covered by Medicaid versus 42% nationally, and that the state’s uninsured rate is lower than the national rate. Members asked about covered services, income limits, federal matching rates, and the names of optional eligibility groups; staff explained that New Hampshire offers the optional groups discussed, with matching rates varying by category, including 90% for Granite Advantage and certain other groups, and 65% for children above the required level. A substantial portion of the hearing covered eligibility rules and recent policy changes. Officials reviewed the history of Medicaid, including HCBS waivers, the CFI program, Katie Beckett, the Olmstead decision, the ACA, and the end of continuous enrollment after the public health emergency. They also discussed the 2023 legislative expansion of postpartum coverage from 60 days to 12 months and child eligibility changes. In response to questions, DHHS said it is tracking utilization and costs for the postpartum expansion and reported that many maternal deaths occur after the prior 60-day coverage period, often involving substance use disorder or suicide; they said the longer coverage is intended to improve access to treatment and prevention. The committee also walked through household-income examples, clarified that Medicaid eligibility is based on household income and categorical rules, and confirmed that Granite Advantage ends at 138% of the federal poverty level unless another categorical basis applies. No votes were taken, and the hearing remained informational.

Transcript Highlights:

• PBMs were originally created to negotiate drug prices with pharmaceutical manufacturers.
• PBMs were originally created to negotiate drug prices with pharmaceutical manufacturers.
• Do you believe that pharmaceutical manufacturers are going to maintain the status quo?
• How do you feel about how pharmaceutical manufacturers would treat that in the event that negotiation

Bills: SB511, SB512, HB591, HB909, HB938, HB1154, HB1187

Keywords: automobile repairs, insurance transparency, repair shop liability, non-OEM parts, policyholder rights, automobile insurance, appraisal process, insurance policyholders, dispute resolution, claim valuation, family leave, insurance, paid leave, employment benefits, caregiver support, behavioral health, crisis services, mental health care, insurance coverage, healthcare access

Transcript Highlights:

• They are legally defined as emergency tools and not regulated pharmaceuticals.
• They are legally defined as emergency tools and not regulated pharmaceuticals.
• products should be made without any government influence or oversight, not to mention that all pharmaceuticals
• Medical journals have maintained a corporate kleptocratic relationship with the pharmaceutical industry

Summary: The Senate Health and Welfare Committee approved the February 10, 2026 minutes and then took up Senate Bill 1346, a measure proposing a two-year pause on mRNA-based COVID-19 products for pregnant women and children. Senator Shippey presented the bill as a targeted safety pause to allow more long-term review, saying it was not a blanket ban and that amendments were likely needed to clarify the bill’s language and the process for reviewing safety data. He also said the committee should send the bill to the 14th order for possible amendments. The committee heard extensive testimony both for and against the bill. Supporters, including Nicholas Holster, Christina Parks, James Thorpe, Laura Dembray, Xavier Figueroa, and several others, argued that mRNA products are unsafe, described them as gene therapy, and cited alleged harms to fertility, pregnancy, children, and broader health outcomes. Opponents, including physician Stephen Montemot, Primo Castro of the Biotechnology Innovation Organization, and parent Stephanie Neymour, argued that mRNA vaccines are not gene therapy, that the bill would restrict parental choice and access to medical care, and that decisions should remain with patients and doctors. Committee members also questioned the bill’s definitions, the legislature’s ability to review scientific data, the scope of the exemption for cancer and genetic disorder therapies, and whether the measure would affect other vaccines. After debate, members expressed mixed views: some supported further work on the bill, while others raised concerns about government overreach, the breadth of the definitions, and whether the legislature had the expertise or mechanism to evaluate safety data. Senator Lenny moved to send SB 1346 to the 14th order for possible amendments, and the motion passed by roll call vote, 5-4. The committee then adjourned.

Transcript Highlights:

• However, it needs to follow the path of all of our drugs and pharmaceuticals that go through.
• It should be a doctor, the patient, and a pharmaceutical outpatient.
• The first thing that I just want to note is that vaccine manufacturers and companies are pharmaceutical
• So when that happened, the vaccine manufacturers... ...and companies, pharmaceutical manufacturers, were
• If you want to see pharmaceutical companies remain solvent or if you want to see us be able to produce

Bills: SB801, SB867, SB2717, SB2919, HJR7, HB4, HB14, HB27, HB42, HB46, HB100, HB111, HB112, HB121, HB126, HB146, HB186, HB223, HB229, HB322, HB367, HB500, HB521, HB640, HB705, HB783, HB1052, HB1056, HB1105, HB1106, HB1178, HB1211, HB1234, HB1306, HB1403, HB1449, HB1506, HB1661, HB1690, HB1871, HB1960, HB2017, HB2078, HB2128, HB2240, HB2243, HB2348, HB2407, HB2512, HB2820, HB2844, HB2853, HB2854, HB2885, HB3000, HB3005, HB3053, HB3057, HB3181, HB3333, HB3372, HB3425, HB3441, HB3516, HB3749, HB3783, HB3812, HB3848, HB3923, HB3963, HB4070, HB4134, HB4157, HB4158, HB4211, HB4449, HB4623, HB4638, HB4687, HB4690, HB4748, HB4749, HB4795, HB4848, HB5093, HB5115, HB5129, HB5138, HB5294, HB5616, HB5629, HB5646, HB5661, HB5672, HB5674, HB5699, HCR40, SJR5, SJR27, SJR59, SB4, SB6, SB8, SB9, SB10, SB12, SB22, SB23, SB25, SB27, SB34, SB36, SB37, SB38, SB40, SB57, SB140, SB261, SB293, SB441, SB447, SB467, SB512, SB650, SB777, SB785, SB924, SB1188, SB1281, SB1318, SB1333, SB1398, SB1448, SB1566, SB1579, SB1621, SB1723, SB1838, SB1862, SB2167, SB2405, SB2406, SB2407, SB2878, SB3059, SB3070, SB1, SB17, SB21, SB260, SB379, SB509, SB1198, SB1405, SB1506, SB1637, SB1833, SB2155, SB2308, SB2601, SB2778, HB300, HB2011, HB2525, HB5246, SJR36, SJR50, SJR63, SCR12, SCR39, SB2023, SB62, SB666, SB847, SB284, SB854, SB810, SB1505, SB583, SB507, SB1434, SB1772, SB2016, SB1122, SB731, SB397, SB508, SB1436, SB287, SB1882, SB393, SB1791, SB209, SB2429, SB1085, SB1975, SB2717, SB1262, SB636, SB2056, SB884, SB1200, SB1845, SB2458, SB801, SB3014, SB3013, SB758, SB2797, SB2076, SB2876, SB1640, SB1449, SB1181, SB1234, SB2926, SB2841, SB1528, SB1854, SB317, SB1250, SB2082, SB1237, SB2819, SB629, SB2608, SB1602, SB2009, SB867, SB640, SB1698, SB2680, SB913, SB1071, SB1086, SB1087, SB1483, SB1444, SB1553, SB1556, SB1703, SB2133, SB2297, SB2298, SB2622, SB2955, SB2334, SB1367, SB2044, SB2363, SB2565, SB1888, SB3036, SB3057, SB3043, SB3063, SB3035, SB203, SB2688, SB2522, SB2459, SB2655, SB2251, SB1884, SB2928, SB2566, SB2549, SB2553, SB2919, SB1944, SB1232, SB1798, SB2603, SB2607, SB2683, SB1319, SB3045, SB3071, HJR7, HB5115, HB3053, HB1403, HB223, HB748, HB5652, HB3395, HB180, HB1306, HB322, HB126, HB5650, HB4894, HB1629, HB5698, HB3171, HB2694, HB5664, HB4690, HB4464, HB3623, HB2520, HB2213, HB252, HB146, HB5596, HB3619, HB5320, HB5651, HB5670, HB5665, HB5437, HB5679, HB5699, HB5661, HB5662, HB5654, HB5672, HB5656, HB3812, HB3057, HB2035, HB721, HB346, HB2512, HB5695, HB5694, HB5674, HB3185, HB2348, HB1871, HB1135, HB101, HB5666, HB5677, HB5682, HB5658, HB4144, HB3642, HB3815, HB2686, HB2012, HB1960, HB227, HB654, HB1690, HB2128, HB4158, HB4630, HB1523, HB2078, HB1973, HB3333, HB3697, HB3546, HB3225, HB3181, HB2820, HB1506, HB1234, HB640, HB521, HB229, HB186, HB119, HB4795, HB4466, HB3749, HB1106, HB4, HB4170, HB3909, HB4081, HB4145, HB4157, HB4285, HB4463, HB4995, HB5138, HB5624, HB1449, HB2598, HB3629, HB4361, HB824, HB1868, HB4848, HB2243, HB40, HB117, HB3686, HB500, HB3793, HB112, HB104, HB1056, HB42, HB3000, HB100, HB2240, HB718, HB27, HB4904, HB4202, HB2853, HB5129, HB5093, HB4765, HB4748, HB4559, HB4350, HB4214, HB3388, HB3112, HB5196, HB4211, HB3516, HB3092, HB4233, HB4687, HB705, HB1094, HB2037, HB3005, HB3848, HB1105, HB121, HB3372, HB367, HB783, HB3336, HB3441, HB4449, HB5616, HB2407, HB2854, HB3425, HB5294, HB1178, HB4623, HB14, HB3963, HB1211, HB5646, HB5629, HB3783, HB4236, HB46, HB4638, HB1052, HB4070, HB5509, HB5435, HB4134, HB3923, HB3520, HB3320, HB2517, HB2488, HB5663, HB2731, HB3073, HB2655, HB2399, HB541, HB4099, HB111, HB1532, HB3483, HB2963, HB4580, HB3748, HB713, HB632, HB426, HB4730, HB127, HB5690, HB5689, HB5655, HB3385, HB2757, HB4359, HB5381, HB20, HB123, HB549, HB5606, HB2217, HB2594, HB796, HB150, HB1057, HCR141, HCR40, HCR59, HCR76, HCR81, HCR46, HCR111, HCR83, HCR84, HJR7, HB4, HB14, HB27, HB42, HB46, HB100, HB126, HB150, HB322, HB367, HB500, HB640, HB705, HB783, HB1105, HB1178, HB1211, HB1234, HB1506, HB1690, HB1871, HB2078, HB2128, HB2240, HB2243, HB2407, HB2512, HB2853, HB2854, HB3000, HB3057, HB3181, HB3372, HB3425, HB3441, HB3749, HB3783, HB3812, HB3923, HB3963, HB4070, HB4134, HB4157, HB4211, HB4449, HB4623, HB4638, HB4687, HB4748, HB4795, HB5093, HB5129, HB5616, HB5629, HB5699, HB229, HB521, HB1056, HB1106, HB5138, SR583, SCR52, HB223, HB229, HB521, HB1056, HB1106, HB1403, HB3053, HB5115, HB5138

Keywords: SB 801, birth certificate, birth record, certified copy, homeless, homelessness, unhoused, vital records, state registrar, local registrar, county clerk, fee waiver, identity documents, ID access, housing insecurity, shelter, transitional housing, Health and Safety Code, HHSC, Health and Human Services Commission

Transcript Highlights:

• initially was that what if somebody wants to, you know, maybe they found a cheaper price on, like, a pharmaceutical
• item on Amazon, and you explained that pharmaceutical items are not part of SNAP.
• So that was... ...explained that pharmaceutical items are not part of SNAP.

Bills: HB4422, HB4117, HB4300, HB4298, HB2984, HB3344

Keywords: immigration, public assistance, legal status, food assistance, state benefits, family resource center, community support, employment services, kinship families, social connections, child care, criminal history, background checks, child safety, licensing, Oklahoma laws, advisory committees, daycare, licensed child care facility, child care subsidy

Summary: The Children, Youth, and Family Committee met for its first meeting, with the chair emphasizing a shared goal of improving outcomes for children and families and describing the bills before the committee as work in progress. The committee first adopted a working draft and heard House Bill 4422, which would require applicants for welfare benefits to be checked through the SAVE system to verify American citizenship; the speaker said amendments removed earlier child-only and WIC changes. The bill was reported out 7-1. The committee then considered several DHS- and child welfare-related measures. House Bill 4117 would broaden the definition of family resource centers to better reflect Oklahoma organizations and support access to public and private grants, including faith-based and workforce-training efforts; it was reported due pass after discussion about the range of services such centers provide. House Bill 4298 would allow child care facilities to receive rule-change notices electronically instead of only by mail, while preserving mail delivery as an option, and House Bill 4300 would add a fingerprint requirement to child care background checks to align state law with federal Child Care Development Fund requirements; both were reported due pass. House Bill 2984 would direct DHS to seek a waiver limiting SNAP purchases to Oklahoma in order to reduce out-of-state card skimming and fraud; members discussed border-area concerns and possible radius exceptions, but the bill was reported out 6-0. The final major measure was House Bill 3344, a foster care bill intended to improve placement and support for foster children and families. The author said the bill was only a starting point and that he had been working with DHS, judges, and other stakeholders; members raised concerns about a felony penalty in the bill, and the author said that provision would be revised as the bill moved forward. The committee passed the bill 7-0. Several members also used the discussion to stress the need for stronger funding for vulnerable populations and state agencies, especially foster care and mental health services. The meeting ended with plans for further revisions and a follow-up meeting the next Wednesday.

Transcript Highlights:

• I'M HERE REPRESENTING TODAY ALSO PHARMACEUTICALS ONE OF OUR CLIENTS GOOD AFTERNOON, YOU ARE RECOGNIZED
• I'M HERE REPRESENTING TODAY ALSO PHARMACEUTICALS ONE OF OUR CLIENTS WHO HAS WORKED WITH CHAIR HARRELL
• PHARMACEUTICALS HAS SUPPORTED AN INITIATIVE SIMILAR TO SENATE BILL 264.

Keywords: 999, senate, all

Transcript Highlights:

• But given where we are today, given the reluctance of payers and providers and pharmaceutical companies
• The amendment excludes spending on pharmaceuticals, including medically administered drugs, from the
• Pharmaceutical costs reflect the price of a drug rather than a direct investment in primary care clinician
• It changes only how pharmaceutical expenditures are counted when calculating the statewide aggregate

Keywords: 1212, all

Transcript Highlights:

• , we are one of only two countries in the world that allow direct-to-consumer advertising for pharmaceuticals
• And you have people that are hearing these ads from the pharmaceutical companies claiming their vaccines
• We hear disclaimers at the end of general pharmaceutical commercials, sometimes all the potential side
• The pharmaceutical companies can educate doctors.

Bills: S0408, S0986, S0678, S0800, S1050, S0484, S1118

Keywords: vaccine advertisement, manufacturer liability, harmful vaccine, healthcare, court action, smoking regulation, public health, vaping, marijuana, public places, Florida Statutes, alcohol distribution, tax deductions, extraordinary losses, warehouse breakage, regulatory compliance, veterinary, prescription, pharmacy, client rights

Transcript Highlights:

• The push to vaccinate ignores that pharmaceuticals historically only care about profits and cover up
• We do not want to have a mandate when pharmaceuticals can decide.
• I have a doctorate in polymer chemistry, and for part of my career, I worked in the pharmaceutical industry
• that the people in Massachusetts are never again required to take an experimental liability-free pharmaceutical
• ..the people in Massachusetts are never again required to take an experimental liability-free pharmaceutical

Keywords: 995, all

Summary: The Joint Committee on Emergency Preparedness and Management held a hearing on several emergency management bills, with most of the testimony focused on Senate Bill 539, which would prohibit COVID-19 mRNA vaccination or gene-altering procedures as a condition of entry, employment, school attendance, or access to public venues. Senator Durant and many public witnesses supported the bill, arguing that COVID-era mandates were coercive, ineffective, and harmful, and that the state should not require proof of vaccination in future emergencies. One witness, Joanne Tuller, testified in opposition, saying the government should retain authority to impose public health measures in emergencies and warning against permanently limiting that power based on the COVID experience. The committee also heard testimony on Senate Bill 540, concerning the prevention of radioactive material discharge, with a Sierra Club representative and local residents opposing Holtec’s disposal of wastewater from the Pilgrim Nuclear Power Plant and citing health, environmental, and economic concerns in Plymouth and nearby communities. Senator Driscoll testified in support of Senate Bills 537 and 538, describing them as measures to strengthen the Commonwealth’s strategic preparedness stockpile and to create a framework for emergency response during surges in hospitalizations, including temporary waivers of prior authorization when hospitals are over capacity. In addition, Dr. Jennifer Carlson testified in support of H.885, a resolve creating a special commission on the field of emergency management, arguing that the profession should be more fully professionalized and staffed by dedicated experts rather than part-time “second hat” officials. Several other bills on the docket, including H.883 and H.84, had no sign-ups. The chair closed each bill’s testimony section as the list was exhausted, and the hearing was adjourned without any votes taken during the session.

Transcript Highlights:

• During COVID, we were unable to procure semiconductors to build our cars or materials for pharmaceuticals
• question I have for you, there's no doubt that we have offshored some very crucial products, pharmaceuticals
• This includes semiconductors, it includes pharmaceuticals. like you're talking about, certain metals
• So we are doing investigations right now, and we're considering, with respect to pharmaceuticals and
• For now, we've excluded pharmaceuticals and semiconductors to take a different kind of Let's get to another

Keywords: tariffs, Trump administration, economy, public testimony, trade policy, market access, export controls

Summary: The meeting focused on various significant topics concerning the recent tariff policies and their wide-ranging implications on the American economy. Members expressed their concerns regarding the negative impact of increased tariffs as proposed by the Trump administration, with specific emphasis on how families might suffer from higher costs and market access issues. The discussion was lively, with members questioning the clarity of the tariff plan and raising concerns about its potential effects on small businesses and American exports.

Transcript Highlights:

• Pharmaceuticals, and we want to do it in a way that's affordable.
• These key components, whether it's specialty metals, minerals, or active pharmaceutical ingredients,
• was surprised to find out is That we really don't produce the precursor chemicals or the active pharmaceutical
• Pharmaceuticals, for sure, is one that I think we need to look at.
• Manufacturing lots and lots of products, including glass, detergent, pharmaceuticals, whether it's oil

Transcript Highlights:

• What you have right here is an avatar for a pharmaceutical related to diabetes and high blood pressure
• c> related</c><00:19:42.160><c> to</c><00:19:42.640><c> diabetes</c><00:19:43.360><c> and</c> pharmaceutical
• related to diabetes and pharmaceutical related to diabetes and high<00:19:43.840><c> blood</c><00:19
• what's happening is that people right now, uh, the money in health care is all going to these pharmaceutical
• </c> all going to these pharmaceutical all going to these pharmaceutical companies.<00:32:12.080><c>

Keywords: 958, all

Summary: A presenter from Fast Health Corporation described a proposed Kentucky Health Command System tied to Senate Bill 175, which would create a state-sanctioned AI platform for rural hospitals and telehealth. The company said the system would help rural residents get health information remotely, triage minor issues, and escalate more serious cases to Kentucky providers, with use cases including blood pressure, diabetes, maternity care, smoking cessation, and other preventive-care topics. The presenter argued the system would help rural hospitals compete with out-of-state telehealth companies and keep patients connected to local care. The presentation also emphasized a commercial model the sponsor said would generate new revenue through ads and branded interactions, with the bill reportedly directing 80% of that revenue to rural hospitals and 20% to the state to maintain the system. The presenter said the technology would augment, not replace, doctors and nurses, and claimed it could improve access and convenience in underserved areas. Committee members raised concerns about liability, whether the AI could provide medical advice, and whether there was evidence it had reduced emergency room visits; the presenter said the system could not give medical advice and acknowledged the technology is still very new. The sponsor of the bill said the goal was to help transform rural health care, reduce unnecessary ER use, and capture revenue that would otherwise go to commercial search engines and out-of-state companies. No vote or final action was taken during the portion of the meeting provided, and the discussion ended with questions about branding, loyalty, and the legal limits of the AI system.

Transcript Highlights:

• My concern is you're saying we want to hold the pharmaceutical company responsible.
• I'm not arguing that point, but it's not the pharmaceutical company that's educating us.
• I noticed in your explanation of the bill, you mentioned something about pharmaceutical companies not
• paying out and claims are just going out. ...something about pharmaceutical companies not paying out
• companies, and I know it's a shock, ...liability cases against pharmaceutical companies, and I know

Summary: The subcommittee first took up HB 339, which would create liability for vaccine manufacturers that advertise in Florida and require them to stand behind their products if consumers are harmed. The sponsor argued the bill is meant to restore trust in vaccines, improve informed consent, and address inadequate federal vaccine-injury compensation systems; he said he was open to amendments and noted the bill was modeled on Texas law. Opponents, including a former vaccine-court official, a Florida Justice Reform Institute representative, and a physician, argued the bill is preempted by federal law, raises First Amendment concerns, is vague, and is unnecessary because existing federal compensation programs already provide a remedy. After an amendment delaying the effective date by three months was adopted, the committee heard extensive public testimony, mostly opposed, and then approved HB 339 as amended by a 12-4 vote. The committee then began HB 1001, a strike-all on official actions of local governments that would bar counties and municipalities from official DEI-related actions and spending, define DEI and related terms, add enforcement provisions, and include broad exceptions for holidays, observances, and certain content-neutral civic events. The sponsor said the measure is intended to curb what he described as divisive and wasteful DEI activity in local government while preserving compliance with anti-discrimination laws and other listed exceptions. Members questioned the lack of definitions for terms like “preferential treatment” and the bill’s possible effects on local festivals, language-access services, Pride events, memorials, and community programs; the sponsor said some concerns were addressed by exceptions and that he was open to further changes. Public testimony was overwhelmingly opposed, with speakers warning of overbreadth, preemption, frivolous lawsuits, harm to local autonomy, and impacts on marginalized communities, while supporters said the bill would restore neutrality, accountability, and merit-based governance. The amendment to HB 1001 was adopted, and the committee continued hearing testimony and debate on the bill as amended.

Transcript Highlights:

• </c><00:49:04.480><c> Care</c><00:49:04.720><c> Management</c> the Pharmaceutical Care Management the
• Pharmaceutical Care Management Association,<00:49:06.480><c> otherwise</c><00:49:06.880><c> known</c
• As an alternative, we suggest an amendment that would require pharmaceutical manufacturers to freeze
• As an alternative, we suggest an amendment that would require pharmaceutical manufacturers to freeze
• Michelle Mack, from the Pharmaceutical Care Management Association, otherwise known as PCMA.

Keywords: 1187, senate, all

Bills: SB2908, SB2671, SB3085, SB2907, SB2353, SB2074, SB2360, SB2057, SB3251, SB2354, SB3001

Keywords: permit processing, permitting reform, county permits, development permits, building permits, land use, construction delays, housing development, infrastructure development, county workforce, differential pay, salary incentive, performance bonus, recruitment and retention, expedited hiring, vacancy rates, permit backlog, government modernization, county mayor, county council

Summary: The committee heard testimony on several Senate bills, with most measures drawing broad support and a few generating significant opposition or policy questions. SB 2908 SD1 and SB 2671 SD1 were taken up first; both appeared to have majority support, with SB 2908 receiving seven in support, one in opposition, and one comment, and SB 2671 receiving five in support and two comments. SB 3085 SD2, related to film industry operations, drew 11 supporters and no opposition. Georgia Skinner explained that the bill would streamline the approval timeline for productions by reducing delays tied to Land Board review, and she said DLNR supported the effort. Committee members asked about the need for the change and the relationship between the film studio, DLNR, and the approval process. The committee then discussed SB 2907 SD1, which would create an Office of Marine Affairs. Testimony was largely supportive, including from DLNR, HTDC, the Department of Agriculture and Biosecurity, ocean industry representatives, and others. The governor’s office supported the bill’s intent but objected to placing the office within the Office of the Governor, urging instead that it be housed at HTDC. HTDC said it was willing and excited to take on the work and described ongoing stakeholder engagement. Members asked about the rationale for the placement and the long-term structure of the office. SB 2353 SD2, concerning the Aloha Stadium district and billboard/naming-rights issues, drew strong opposition overall, with four in support, 23 in opposition, and one comment. Andrew Pereira of the Stadium Authority argued the measure could generate revenue to help maintain and operate the stadium and said the district would remain self-contained; he also emphasized that the development would respect the character of the area. The committee then heard SB 2074 SD1, which had five in support and 26 in opposition; only one support testimony from the Carpenters was heard before the discussion moved on. Finally, SB 2360 SD1, an enterprise zones measure, received 14 supportive testimonies and two comments. Testimony focused on updating the program for modern business models, especially e-commerce and direct-to-consumer sales, while committee members questioned whether the program overlaps with higher tax burdens and whether businesses receiving subsidies should be monitored for job retention after graduation from the program.

Transcript Highlights:

• But given where we are today, given the reluctance of payers and providers and pharmaceutical companies
• The amendment excludes spending on pharmaceuticals, including medically administered drugs, from the
• Pharmaceutical costs reflect the price of a drug rather than a direct investment in primary care clinician
• It changes only how pharmaceutical expenditures are counted when calculating the statewide aggregate

Summary: The Senate first considered several amendments to a primary care/health care bill. Amendment 1, on artificial intelligence in health care and mental health services, was withdrawn by unanimous consent. Amendment 37, which would have required a rate band for outpatient primary care reimbursement, was debated and then defeated on a roll call, 5-33. Amendment 39, on direct primary care arrangements and deductible credits, was also defeated 5-33. The chamber then took up and passed the conference report for An Act Relative to Teachers Preparation and Student Literacy (H. 5511), with senators emphasizing the need for evidence-based literacy instruction, universal screening, dyslexia screening, teacher training, and implementation funding; the bill was enacted and sent to the Governor after a 39-0 roll call. The Senate then returned to Amendment 60 on the primary care bill, which would have created a “safety valve” allowing alternative payment systems to be proposed to the Health Policy Commission. After debate over whether the bill already allowed flexibility, the amendment was defeated 5-33. Amendment 50, requiring stronger health equity reporting, was adopted. Amendment 66, a technical fix setting commercial payment rates for community health centers at the MassHealth PPS rate, was adopted. Amendment 24, excluding pharmaceutical spending from the primary care spending baseline and target, was adopted. Amendment 45, a study on expanding the role of allied health professionals, was withdrawn. Amendment 48, a group purchasing cooperative pilot, and amendments 53, 61, and 63 were also withdrawn. The Senate adopted Amendment 64, which prohibits prior authorization from delaying FDA-approved medications for serious mental illness, and rejected Amendment 68 on reporting private equity investment in primary and specialty care, as well as Amendments 71 and 72 on scope of practice and ownership disclosure. Amendment 62, a technical change modernizing the definition of primary care and clarifying the care team, was adopted. Amendment 21, the Senate Ways and Means amendment, was then adopted, the bill was ordered to a third reading, and the Senate passed An Act relative to primary care for you (S. 3116) to be engrossed on a 35-4 roll call. The Senate then adjourned to a later date, with memorial references at adjournment.

Transcript Highlights:

• They are legally defined as emergency tools and not regulated pharmaceuticals.
• They are legally defined as emergency tools and not regulated pharmaceuticals.
• products should be made without any government influence or oversight, not to mention that all pharmaceuticals
• Medical journals have maintained a corporate kleptocratic relationship with the pharmaceutical industry

Keywords: 989, all

Summary: The Senate Health and Welfare Committee approved the February 10, 2026 minutes and then took up Senate Bill 1346, which would place a two-year moratorium on mRNA-based COVID-19 products for pregnant women and children, with exemptions for certain gene therapies, cancer, genetic disorders, clinical trials, and compassionate use. Senator Shippy presented the bill as a child-safety and informed-consent measure, arguing Idaho should act independently of federal agencies and that the bill was a temporary pause rather than a blanket ban. He also said the bill language still needed clarification and asked that it be sent to the 14th order for possible amendments. The committee heard extensive testimony both for and against the bill. Supporters, including Nicholas Holster, Christina Parks, James Thorpe, Laura Demeray, Xavier Figueroa, Gordon Wilkerson, and others, argued that mRNA products are unsafe, that there are serious reported adverse events and contamination concerns, and that the state should protect children and pregnant women until more long-term data is available. Opponents, including Stephen Montemot, Primo Castro, Amaya Donahue, and Stephanie Nemore, argued that mRNA vaccines are not gene therapy, that the bill would interfere with parental choice and physician judgment, and that it could disrupt access to approved medical care and research. Several senators questioned the bill’s definitions, the process for reviewing safety data, interstate commerce implications, and the scope of the moratorium. After debate, Senator Lenney moved to send SB 1346 to the 14th order for possible amendments. Senators raised concerns about the legislature’s ability to evaluate scientific evidence and about the breadth of the bill’s definitions, while others said the bill’s intent was reasonable but needed cleanup. The motion passed by a 5-4 roll call vote, and the committee adjourned.

Transcript Highlights:

• captured; 19 of the 20 leaders on the nutrition guidelines committee are paid for by the food... pharmaceutical
• Because the medical... guidelines are created by the American Medical Association, which is a pharmaceutical
• because of both government incentives and lack of transparency and accountability, the food and pharmaceutical
• Pharmaceutical interventions have to become central to Texas health policy.

Bills: SB 25, SB25, SB314

Keywords: attorney ad litem, indigent parents, parent-child relationship, legal representation, Texas Family Code, court procedures, nutrition, health standards, food labeling, education, dietary guidelines, medical education, food safety, school meals, child nutrition, food additives, public health, 1185, senate, all